{"id":"heme-arginate-l-arginine","safety":{"commonSideEffects":[{"rate":null,"effect":"Phlebitis at infusion site"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"In acute intermittent porphyria and related acute porphyrias, heme deficiency triggers overproduction of toxic porphyrin precursors. Heme arginate (a heme-albumin complex) directly replenishes heme and suppresses ALA synthase, the rate-limiting enzyme in porphyrin synthesis. L-arginine augments this effect by serving as a substrate for nitric oxide synthase, promoting vasodilation and reducing the hypertensive and vasoconstrictor complications characteristic of acute porphyria attacks.","oneSentence":"Heme arginate replenishes depleted heme pools while L-arginine provides substrate for nitric oxide synthesis, together improving endothelial function and reducing vasoconstriction in acute porphyria crises.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:31:57.639Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute intermittent porphyria (acute attack management)"},{"name":"Variegate porphyria (acute attack management)"},{"name":"Hereditary coproporphyria (acute attack management)"}]},"trialDetails":[{"nctId":"NCT00856817","phase":"PHASE4","title":"Heme Oxygenase (HO) Activity and Adenosine Induced Vasodilation","status":"TERMINATED","sponsor":"Radboud University Medical Center","startDate":"2009-03","conditions":"Atherosclerotic Cardiovascular Disease","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Heme arginate + L-arginine","genericName":"Heme arginate + L-arginine","companyName":"Radboud University Medical Center","companyId":"radboud-university-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Heme arginate replenishes depleted heme pools while L-arginine provides substrate for nitric oxide synthesis, together improving endothelial function and reducing vasoconstriction in acute porphyria crises. Used for Acute intermittent porphyria (acute attack management), Variegate porphyria (acute attack management), Hereditary coproporphyria (acute attack management).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}